Abstract:Tumor progression depends primarily on vascular supply, which is facilitated by angiogenic activity within the malignant tissue. Non-small cell lung cancer (NSCLC) is a highly vascularized tumor, and inhibition of angiogenesis was projected to be a promising therapeutic approach. Over a decade ago, the first anti-angiogenic agents were approved for advanced stage NSCLC patients, however, they only produced a marginal clinical benefit. Explanations why anti-angiogenic therapies only show modest effects include the highly adaptive tumor microenvironment (TME) as well as the less understood characteristics of the tumor vasculature. Today, advanced methods of in-depth characterization of the NSCLC TME by single cell RNA sequencing (scRNA-Seq) and preclinical observations enable a detailed characterization of individual cancer landscapes, allowing new aspects for a more individualized inhibition of angiogenesis to be identified. Furthermore, the tumor vasculature itself is composed of several cellular subtypes, which closely interact with other cellular components of the TME, and show distinct biological functions such as immune regulation, proliferation, and organization of the extracellular matrix. With these new insights, combinational approaches including chemotherapy, anti- angiogenic and immunotherapy can be developed to yield a more target-oriented anti-tumor treatment in NSCLC. Recently, anti-angiogenic agents were also shown to induce the formation of high endothelial venules (HEVs), which are essential for the formation of tertiary lymphoid structures, and key components in triggering anti-tumor immunity. In this review, we will summarize the current knowledge of tumor-angiogenesis and corresponding anti-angiogenic therapies, as well as new aspects concerning characterization of tumor-associated vessels and the resulting new strategies for anti-angiogenic therapies and vessel inhibition in NSCLC. We will further discuss why anti-angiogenic therapies form an interesting backbone strategy for combinational therapies and how anti-angiogenic approaches could be further developed in a more personalized tumor-oriented fashion with focus on NSCLC.

Newly developed anti-angiogenic therapy in non-small cell lung cancer

New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer

Advances In Combination Of Antiangiogenic Agents Targeting Vegf-Binding And Conventional Chemotherapy And Radiation For Cancer Treatment

Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer

Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer

The Potential of Antiangiogenic Therapy in Non–Small Cell Lung Cancer

The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC.

The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer – New Combinational Approaches and Strategies of Neovessel Inhibition

The Story of Angiogenesis Inhibitors in Non–small-cell Lung Cancer: The Past, Present, and Future

The Role of Anti-angiogenesis in Non-small-cell Lung Cancer: an Update

&Lt;p>anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer</p>

Novel Active Agents in Patients with Advanced NSCLC Without Driver Mutations Who Have Progressed after First-Line Chemotherapy

Anti-Angiogenics: Their Value in Lung Cancer Therapy

Anti-angiogenic therapy for colorectal cancer: on the way to getting better!

Targeted Therapies for Patients with Advanced NSCLC Harboring Wild-Type EGFR: What’s New and What’s Enough

The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer

Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives

Emerging angiogenesis inhibitors for non-small cell lung cancer

VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy